S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
LAVAL, QC - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a prominent player in the pharmaceuticals industry with a market capitalization of $2 billion, and its aesthetic business unit, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of its Thermage® system. This system is designed for non-invasive skin tightening and contouring. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates.
Thermage FLX is the fourth iteration of Solta Medical’s monopolar radiofrequency technology and has been a trusted name in non-invasive skin tightening for over two decades. The new system promises to deliver faster treatments with a larger treatment tip, enhanced patient comfort through integrated vibration and cooling, and personalized treatments with its smart impedance technology.
Thomas J. Appio, CEO of Bausch Health, expressed that the clearance of Thermage FLX in Canada marks a significant step for the company’s growth in the aesthetic sector. The company has demonstrated solid performance with revenue growth of 9.9% in the last twelve months, reaching $9.6 billion. Jiny Kim, Senior Vice President at Solta Medical, highlighted the system’s features, including its ergonomic design, which aims to improve the provider’s ease of use and patient comfort.
The device is versatile, suitable for treating wrinkles and rhytids on various areas of the face, eyes, and body, including delicate skin. The approval of Thermage FLX in Canada is expected to provide Canadian providers and patients access to the same technology already used by leading aesthetic clinics globally.
Solta Medical is known for its portfolio of medical aesthetic technologies, and the addition of Thermage FLX is anticipated to strengthen its market position. Bausch Health, a global pharmaceutical company, has a diverse product range and maintains a controlling interest in Bausch + Lomb Corporation. The company’s aesthetic business is recognized for its medical aesthetic technologies.
This announcement is based on a press release statement and includes forward-looking statements subject to risks and uncertainties. These statements are not guarantees of future performance and are based on current expectations. Bausch Health has emphasized that it undertakes no obligation to update any forward-looking statements post this news release.
The clearance of Thermage FLX by Health Canada is a noteworthy development for Bausch Health, potentially impacting the company’s future in the aesthetic medical device market.
In other recent news, Bausch Health Companies Inc. has announced the launch of its new skin resurfacing technology, Fraxel FTX™, at the ASLMS 2025 Annual Conference. This innovation is part of the company’s strategy to enhance aesthetic medicine and is set to be available to professionals across the United States, with plans for global expansion. Additionally, Bausch Health disclosed that activist investor Carl Icahn holds an economic interest in approximately 34% of the company’s shares through equity swaps. This development was part of an updated proxy statement for the upcoming annual meeting, highlighting Icahn’s significant financial exposure.
The company also adopted a shareholder rights plan to prevent any single entity from acquiring more than 20% of its shares without meeting specific conditions. In a separate legal matter, Bausch Health secured a favorable court ruling that maintains market exclusivity for its product XIFAXAN® until at least June 2028. This decision alleviates concerns about potential generic competition for the drug.
Furthermore, Fitch Ratings upgraded the Issuer Default Rating of Bausch + Lomb Corporation, a subsidiary of Bausch Health, reflecting a positive outlook for the company. This upgrade follows a similar action for Bausch Health itself, indicating improved financial stability. These recent developments collectively underscore Bausch Health’s strategic efforts to strengthen its market position and governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.